• PDF / 168,948 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 19 Downloads / 128 Views

DOWNLOAD

REPORT

---

1 S

Immune checkpoint inhibitor-related diarrhoea and colitis: case report In a study of 519 patients treated between 2011 and 2016, a patient [age and sex not stated] was described, who developed immune-related diarrhoea and colitis during treatment with ipilimumab and nivolumab for advanced melanoma. The patient, who had advanced melanoma started receiving treatment with ipilimumab and nivolumab every 2 weeks [doses and routes not stated]. However, during treatment the patient developed immune-related diarrhoea and colitis associated with ipilimumab and nivolumab [durations of treatments to reactions onset and outcomes not stated ] Favara DM, et al. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced 803497013 melanoma. ESMO Open 5: 1-8, No. 4, 2020. Available from: URL: http://doi.org/10.1136/esmoopen-2019-000585

0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 22 Aug 2020 No. 1818